Literature DB >> 11293807

Epidemiology and clinical features of HIV-1 associated neuropathies.

A Verma1.   

Abstract

Peripheral neuropathy is common in human immunodeficiency virus type-1 (HIV-1) infection. Peripheral neuropathies complicate all stages of the HIV-1 disease and cause considerable morbidity and disability in HIV-1 infected individuals and acquired immunodeficiency syndrome (AIDS) patients. Whereas symptomatic neuropathies occur in approximately 10% to 15% of HIV-1-infected patients overall, pathologic evidence of peripheral nerve involvement is present in virtually all end-stage AIDS patients. There are 6 major clinical types of HIV-associated neuropathies that are regularly seen in large HIV-1 clinics. Distal sensory polyneuropathy (DSP) is the most common among the HIV-1-associated neuropathies. DSP generally occurs in later stages of HIV-1 infection and it follows an indolent and protracted clinical course. The dominant clinical features in DSP include distal pain, paresthesia and numbness in a typical length-dependent fashion with proximal to distal gradient. Whereas toxic neuropathies--secondary to certain antiretroviral agents--are clinically similar to DSP, their temporal relation to neurotoxic medication helps distinguish them from other HIV-1-associated neuropathies. DSP and toxic neuropathy may coexist in a single patient. Acute and chronic inflammatory demyelinating polyradiculoneuropathies (AIDP and CIDP) produce global limb weakness. AIDP may occur at seroconversion and it can therefore be the initial manifestation of HIV-1 infection. CIDP generally occurs in the mid to late stages of HIV-1 infection. Progressive polyradiculopathy (PP) occurs in patients with advanced immunodeficiency and is generally caused by the opportunist cytomegalovirus (CMV) infection. Mononeuropathy multiplex (MM) in early stages of HIV-1 infection is immune mediated, whereas in advanced AIDS it is caused by the CMV infection. Finally, subclinical autonomic nervous system involvement is common in all stages of HIV-1 infection. Because HIV-1-associated neuropathies are diverse in their etiology and pathogenesis, a precise clinical diagnosis is required to formulate a rational therapeutic intervention.

Entities:  

Mesh:

Year:  2001        PMID: 11293807     DOI: 10.1046/j.1529-8027.2001.006001008.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  21 in total

Review 1.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

Review 2.  HIV-associated neuropathic pain: epidemiology, pathophysiology and management.

Authors:  Susama Verma; Lydia Estanislao; David Simpson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Gene therapy with HSV encoding p55TNFR gene for HIV neuropathic pain: an evidence-based mini-review.

Authors:  Hirotsugu Kanda; Shue Liu; Megumi Kanao; Hyun Yi; Takafumi Iida; Wan Huang; Takayuki Kunisawa; David A Lubarsky; Shuanglin Hao
Journal:  Transl Perioper Pain Med       Date:  2017

Review 4.  [HIV-associated neuropathies].

Authors:  K Hahn; I W Husstedt
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

Review 5.  Uses of skin biopsy for sensory and autonomic nerve assessment.

Authors:  M Iliza Myers; Amanda C Peltier
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 6.  Neurologic presentations of AIDS.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah Commins; Andrew Levine
Journal:  Neurol Clin       Date:  2010-02       Impact factor: 3.806

7.  Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathy.

Authors:  Susan G Dorsey; Carmen C Leitch; Cynthia L Renn; Sherrie Lessans; Barbara A Smith; Xiao M Wang; Raymond A Dionne
Journal:  Biol Res Nurs       Date:  2009-07       Impact factor: 2.522

8.  Animal models of HIV peripheral neuropathy.

Authors:  Tricia H Burdo; Andrew D Miller
Journal:  Future Virol       Date:  2014-05-01       Impact factor: 1.831

9.  Central activation, muscle performance, and physical function in men infected with human immunodeficiency virus.

Authors:  Wayne B Scott; Krisann K Oursler; Leslie I Katzel; Alice S Ryan; David W Russ
Journal:  Muscle Nerve       Date:  2007-09       Impact factor: 3.217

Review 10.  Biology of the human blood-nerve barrier in health and disease.

Authors:  Eroboghene E Ubogu
Journal:  Exp Neurol       Date:  2020-03-03       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.